Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Blood (2024) 144 (Supplement 1): 845.

https://doi.org/10.1182/blood-2024-201097

Published: 2024

Journal Articles

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Blood (2024) 144 (Supplement 1): 59.

https://doi.org/10.1182/blood-2024-200027

Published: 2024

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

Nigel H. Russell, Abin Thomas, Robert Hills, Ian Thomas, Amanda Gilkes, Nuria Almuina, Sarah Burns, Lucy Marsh, Georgia Andrew, Nicholas McCarthy, Jennifer Byrne, Rob Sellar, Richard J. Kelly, Paul Cahalin, Ulrik Malthe Overgaard, Priyanka Mehta, Mike Dennis, Steve Knapper, Sylvie D Freeman

Blood (2023) 142 (Supplement 1): 830.

https://doi.org/10.1182/blood-2023-185956

Published: 2023

Journal Articles

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Blood (2023) 142 (Supplement 1): 746.

https://doi.org/10.1182/blood-2023-173127

Published: 2023

Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell

Blood (2023) 142 (Supplement 1): 425.

https://doi.org/10.1182/blood-2023-179033

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Anders Lindholm Lindholm Sørensen, Vibe Skov, Lasse Kjær, Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Morten Kranker Larsen, Claus Nielsen, Carsten Thomsen, Lise Mette Rahbek Gjerdrum, Trine Alma Knudsen, Christina Ellervik, Ulrik Malthe Overgaard, Christen Lykkegaard Andersen, Mads Emil Bjørn, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 6806–6807.

https://doi.org/10.1182/blood-2022-157397

Published: 2022

Journal Articles

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Jad Othman, Richard Dillon, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panos Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell

Blood (2022) 140 (Supplement 1): 1036–1038.

https://doi.org/10.1182/blood-2022-159433

Published: 2022

Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Blood (2022) 140 (Supplement 1): 1794–1796.

https://doi.org/10.1182/blood-2022-156445

Published: 2022

Journal Articles

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis

Blood (2022) 140 (Supplement 1): 526–528.

https://doi.org/10.1182/blood-2022-162377

Published: 2022

Journal Articles

Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study

Merete Eybye Dam, Maddalena Centanni, Lena Friberg, Mats Karlsson, Line Stensig Lynggaard, Inga M. Johannsdottir, Hilde Skuterud Wik, Mats Heyman, Johan Malmros, Helene Hallböök, Goda Elizabeta Vaitkeviciene, Laimonas Griskevicius, Ólafur Gísli Jónsson, Ulrik Malthe Overgaard, Kjeld Schmiegelow, Birgitte Klug Albertsen

Blood (2022) 140 (Supplement 1): 8886–8887.

https://doi.org/10.1182/blood-2022-168655

Published: 2022

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Blood (2019) 134 (Supplement_1): 3820.

https://doi.org/10.1182/blood-2019-122275

Published: 2019

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia: A National Population-Based Cohort Study

Michael Buch Tostesen, MD, Jan M. Norgaard, MD PhD, Mette Nørgaard, MD PhD, Bruno C. Medeiros, MD, Claus Werenberg Marcher, MD PhD, Ulrik Malthe Overgaard, MD, Claudia Schöllkopf, MD PhD, Marianne Tang Severinsen, MD PhD, Lene Sofie Granfeldt Oestgaard, MDPhD

Blood (2018) 132 (Supplement 1): 613.

https://doi.org/10.1182/blood-2018-99-110922

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 580.

https://doi.org/10.1182/blood-2018-99-111255

Published: 2018

Journal Articles

Autoimmune Diseases, Infections, Use of Antibiotics and the Risk of Acute Myeloid Leukemia: A National Population-Based Case-Control Study

Lene Sofie Granfeldt Østgård, MD PhD, Mette Nørgaard, MD PhD, Lars Pedersen, MSc, PhD, René Østgård, MD PhD, Ulrik Malthe Overgaard, MD, Claudia Schöllkopf, MD PhD, Marianne Tang Severinsen, MD PhD, Claus Werenberg Marcher, MD PhD, Morten Krogh Jensen, MD Dr.MDSci

Blood (2017) 130 (Supplement 1): 1304.

https://doi.org/10.1182/blood.V130.Suppl_1.1304.1304

Published: 2017

Journal Articles

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Lukas Frans Ocias, Dennis Lund Hansen, Thomas Kielsgaard Kristensen, Karin de Stricker, Daniel El Fassi, MD PhD, Jesper Stentoft, Jørn Starklint, Mikael Frederiksen, Marianne Tang Severinsen, Ole Weis Bjerrum, MD DMSc, Peter Møller, Torben Mourits-Andersen, MD, Ulrik Malthe Overgaard, Hans Carl Hasselbalch, MD Professor, DMSc, Klaus Bendtzen, Thomas Stauffer Larsen, MD PhD

Blood (2015) 126 (23): 5177.

https://doi.org/10.1182/blood.V126.23.5177.5177

Published: 2015

NARROW

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia: A National Population-Based Cohort Study

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Autoimmune Diseases, Infections, Use of Antibiotics and the Risk of Acute Myeloid Leukemia: A National Population-Based Case-Control Study

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only